10 states with the most guns per capita:
1. Montana (66.4% of adults)
2. Wyoming (66% of adults)
3. Alaska (64.5% of adults)
4. Idaho (60.1% of adults)
5. WV (58.5% of adults)
6. AR (57.2% of adults)
7. MS (56.3% of adults)
8. AL (55.2% of adults)
9. SD (55.1% of adults)
10. ND (55% of adults)
All 10 of these states support the Texas Border Resistance against the federal government.
Levemir, a Long-Acting Insulin, To Be Discontinued by Novo Nordisk
https://diatribe.org/levemir-long-acting-insulin-be-discontinued-novo-nordisk
Excerpt:
evemir, a long-acting insulin for people with diabetes, will be discontinued by Novo Nordisk in 2024.
It’s the end of the production line for one of Novo Nordisk’s best selling products.
Levemir (insulin detemir), a long-acting basal insulin that is commonly used by people with diabetes on multiple daily injections of insulin, will be discontinued in the US in 2024, the company announced.
When will Levemir be discontinued?
According to Novo Nordisk, Levemir FlexPen, the injection pen version of insulin detemir, will likely face supply disruption starting in mid-January 2024, lasting up until the FlexPen’s discontinuation on April 1. Levemir in vials will no longer be available after Dec. 31, 2024. The company also warned of imminent shortages of Levemir due to supply chain issues.
Why is Levemir being discontinued?
Novo Nordisk has said that it will discontinue Levemir in the States by the end of next year “due to global manufacturing constraints, formulary losses impacting patient access, and the availability of alternative options.”
This news comes just months after Novo Nordisk announced plans in March to cut insulin prices by as much as 75% beginning Jan. 1. Novo’s plan for price cuts was announced shortly after competitor Eli Lilly announced it would be capping insulin costs at $35 per month amidst mounting pressure from lawmakers as Americans struggle to afford insulin.
“We made this decision after careful consideration, and are confident that patients will be able to access alternative treatments in the US,” the company said in the statement, along with a recommendation that healthcare providers discuss treatment options with their patients in advance of discontinuation.
.....As newer, better-performing basal insulins enter the market – this includes the company’s own Tresiba, as well as the expected availability of once-weekly insulins in the future – older generation products, such as those that are injected twice daily, are in line to be phased out.
Levemir represents a sizable portion of the basal insulin market (it generated $649 million in revenue in 2022 alone). As a commonly used basal insulin that people with diabetes rely on to manage their blood sugar, its discontinuation – particularly near the onset of a significant price cut – is likely to affect consumers, reducing access to medications for many.
Don’t tell Governor Jelly Belly Prickster from the Peoples Republic of Ill-Annoy that 80% of people here probably have guns, and probably 95% in Chiraq own guns.